Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
simethicone + pronase
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral
01
Overview
A combination premedication used before upper gastrointestinal endoscopy procedures to improve mucosal visibility. Simethicone acts as a defoaming agent that reduces gas bubbles, while pronase functions as a mucolytic enzyme that breaks down mucus in the stomach. Together, they significantly enhance the clarity of the endoscopic visual field, which can improve diagnostic accuracy and potentially increase the detection of early cancers and precancerous lesions.
02
Targets
MUC2 (Mucin-2)
Beyond the preview
Go deeper on simethicone + pronase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on simethicone + pronase.